Unlocking Pan-Cancer Detection with Phenyl-β-D-Glucuronide Like Exogenous Agent and Induced Breath Analysis for Non-Invasive Early Discovery

The urgent need for a non-invasive, universally applicable cancer detection method has never been more critical. In response to the pressing demand, we presents the discovery of phenyl-β-D-glucuronide, a natural compound, for tumor detection. Metabolized into phenol by β-glucuronidase, an enzyme prevalent in the tumor microenvironment, this compound led to elevated phenol levels in exhaled breath. Moreover, phenyl-β-D-glucuronide's exceptional bio-compatibility and minimal residual presence post-24 hours offer unparalleled advantages over conventional synthetic agents. Building upon this innovation, we created a cutting-edge cancer screening method known as phenyl-β-D-glucuronide induced breath analysis. Specifically, a handheld breath-analyzer is proposed to capture breath signals indicative of cancer presence. Preliminary animal tests, utilizing both subcutaneous and orthotopic tumors model, validated the effectiveness of our method in assessing various cancer risk, including gastric, lung, colon and liver cancers, with specificity/sensitivity/accuracy rates surpassing 94.3%; and minimal interference from other diseases. These impressive findings mark a significant step toward cancer detection, improving diagnosis and treatment outcomes universally.